Stance control orthosis trial in patients with inclusion body myositis

Kathie Bernhardt, Terry Oh, Kenton R Kaufman

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Inclusion Body Myositis (IBM) is an inflammatory myopathy that commonly affects quadriceps strength, resulting in knee buckling and falls. Therefore, patients with IBM should be ideal candidates for stance control orthoses (SCOs). Objectives: Evaluate the effectiveness of SCO use in patients with IBM who have functional deficits due to quadriceps weakness. Study Design: Cohort study. Methods: Nine subjects with IBM were provided a stance control orthosis and followed for six months of home use. All patients had objective testing of their strength and gait and completed a questionnaire at baseline and six months. Gait analysis was performed both with and without the orthosis. Results: Velocity and cadence were lower and step width was higher when using the orthosis. Kinematic measures were largely unchanged with orthosis use. Subjects with less knee extensor weakness had a better outcome than weaker participants. Those who spent more time wearing the orthosis also had a more positive outcome. The participants felt that the SCO was helpful in safeguarding against falls and providing stability. Conclusions: SCO use will benefit patients with IBM, but care should be taken to choose the SCO option that best suits their individual clinical presentation. Clinical relevance: This is the first study to examine SCO use in the IBM population. Patients with IBM have quadriceps weakness and will potentially benefit from SCO use. This study suggests that successful SCO management of patients with IBM depends on severity of weakness.

Original languageEnglish (US)
Pages (from-to)39-44
Number of pages6
JournalProsthetics and Orthotics International
Volume35
Issue number1
DOIs
StatePublished - Mar 2011

Fingerprint

Inclusion Body Myositis
Orthotic Devices
Gait
Knee
Myositis
Biomechanical Phenomena

Keywords

  • Control orthosis
  • Field trial
  • Gait stance
  • Inclusion body myositis
  • Knee orthosis

ASJC Scopus subject areas

  • Rehabilitation
  • Health Professions (miscellaneous)

Cite this

Stance control orthosis trial in patients with inclusion body myositis. / Bernhardt, Kathie; Oh, Terry; Kaufman, Kenton R.

In: Prosthetics and Orthotics International, Vol. 35, No. 1, 03.2011, p. 39-44.

Research output: Contribution to journalArticle

@article{0fea2fb8497d4eba8ef8ceae7156cfce,
title = "Stance control orthosis trial in patients with inclusion body myositis",
abstract = "Background: Inclusion Body Myositis (IBM) is an inflammatory myopathy that commonly affects quadriceps strength, resulting in knee buckling and falls. Therefore, patients with IBM should be ideal candidates for stance control orthoses (SCOs). Objectives: Evaluate the effectiveness of SCO use in patients with IBM who have functional deficits due to quadriceps weakness. Study Design: Cohort study. Methods: Nine subjects with IBM were provided a stance control orthosis and followed for six months of home use. All patients had objective testing of their strength and gait and completed a questionnaire at baseline and six months. Gait analysis was performed both with and without the orthosis. Results: Velocity and cadence were lower and step width was higher when using the orthosis. Kinematic measures were largely unchanged with orthosis use. Subjects with less knee extensor weakness had a better outcome than weaker participants. Those who spent more time wearing the orthosis also had a more positive outcome. The participants felt that the SCO was helpful in safeguarding against falls and providing stability. Conclusions: SCO use will benefit patients with IBM, but care should be taken to choose the SCO option that best suits their individual clinical presentation. Clinical relevance: This is the first study to examine SCO use in the IBM population. Patients with IBM have quadriceps weakness and will potentially benefit from SCO use. This study suggests that successful SCO management of patients with IBM depends on severity of weakness.",
keywords = "Control orthosis, Field trial, Gait stance, Inclusion body myositis, Knee orthosis",
author = "Kathie Bernhardt and Terry Oh and Kaufman, {Kenton R}",
year = "2011",
month = "3",
doi = "10.1177/0309364610389352",
language = "English (US)",
volume = "35",
pages = "39--44",
journal = "Prosthetics and Orthotics International",
issn = "0309-3646",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - Stance control orthosis trial in patients with inclusion body myositis

AU - Bernhardt, Kathie

AU - Oh, Terry

AU - Kaufman, Kenton R

PY - 2011/3

Y1 - 2011/3

N2 - Background: Inclusion Body Myositis (IBM) is an inflammatory myopathy that commonly affects quadriceps strength, resulting in knee buckling and falls. Therefore, patients with IBM should be ideal candidates for stance control orthoses (SCOs). Objectives: Evaluate the effectiveness of SCO use in patients with IBM who have functional deficits due to quadriceps weakness. Study Design: Cohort study. Methods: Nine subjects with IBM were provided a stance control orthosis and followed for six months of home use. All patients had objective testing of their strength and gait and completed a questionnaire at baseline and six months. Gait analysis was performed both with and without the orthosis. Results: Velocity and cadence were lower and step width was higher when using the orthosis. Kinematic measures were largely unchanged with orthosis use. Subjects with less knee extensor weakness had a better outcome than weaker participants. Those who spent more time wearing the orthosis also had a more positive outcome. The participants felt that the SCO was helpful in safeguarding against falls and providing stability. Conclusions: SCO use will benefit patients with IBM, but care should be taken to choose the SCO option that best suits their individual clinical presentation. Clinical relevance: This is the first study to examine SCO use in the IBM population. Patients with IBM have quadriceps weakness and will potentially benefit from SCO use. This study suggests that successful SCO management of patients with IBM depends on severity of weakness.

AB - Background: Inclusion Body Myositis (IBM) is an inflammatory myopathy that commonly affects quadriceps strength, resulting in knee buckling and falls. Therefore, patients with IBM should be ideal candidates for stance control orthoses (SCOs). Objectives: Evaluate the effectiveness of SCO use in patients with IBM who have functional deficits due to quadriceps weakness. Study Design: Cohort study. Methods: Nine subjects with IBM were provided a stance control orthosis and followed for six months of home use. All patients had objective testing of their strength and gait and completed a questionnaire at baseline and six months. Gait analysis was performed both with and without the orthosis. Results: Velocity and cadence were lower and step width was higher when using the orthosis. Kinematic measures were largely unchanged with orthosis use. Subjects with less knee extensor weakness had a better outcome than weaker participants. Those who spent more time wearing the orthosis also had a more positive outcome. The participants felt that the SCO was helpful in safeguarding against falls and providing stability. Conclusions: SCO use will benefit patients with IBM, but care should be taken to choose the SCO option that best suits their individual clinical presentation. Clinical relevance: This is the first study to examine SCO use in the IBM population. Patients with IBM have quadriceps weakness and will potentially benefit from SCO use. This study suggests that successful SCO management of patients with IBM depends on severity of weakness.

KW - Control orthosis

KW - Field trial

KW - Gait stance

KW - Inclusion body myositis

KW - Knee orthosis

UR - http://www.scopus.com/inward/record.url?scp=79959195718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959195718&partnerID=8YFLogxK

U2 - 10.1177/0309364610389352

DO - 10.1177/0309364610389352

M3 - Article

C2 - 21515888

AN - SCOPUS:79959195718

VL - 35

SP - 39

EP - 44

JO - Prosthetics and Orthotics International

JF - Prosthetics and Orthotics International

SN - 0309-3646

IS - 1

ER -